Compare Abbott Laboratories (ABT) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Vanguard Real Estate Index Fund ETF — how do they compare? Abbott Laboratories trades at $95.34 (market cap $166.94B), while Vanguard Real Estate Index Fund ETF trades at $96.97. The key difference: Abbott Laboratories pays a 2.63% dividend while Vanguard Real Estate Index Fund ETF pays none, and Vanguard Real Estate Index Fund ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | VNQ | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | — |
52-Week High | $136.62 | $98.66 |
52-Week Low | $82.57 | $87.00 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
VNQ (Vanguard Real Estate ETF) trades at $97.24, down 0.8% on the day, with technical indicators showing a bullish trend supported by moving averages. The ETF's recent performance reflects renewed investor interest in REITs amid shifting rate expectations, with June 2026 marking the sector's best monthly performance in years according to market data. Dividend payments remain a key attraction, with the next distribution scheduled for June 2026.
The outlook for VNQ appears cautiously optimistic as REIT fundamentals show resilience despite elevated interest rates. Investment opportunity lies in potential rate stabilization and sector rotation, while risks include persistent inflation pressure and Treasury yield volatility. Analyst sentiment is mixed, with some highlighting discounted valuations while others caution about sector-specific challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
